Cargando…

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

The standard therapy for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA) which has shown to improve hepatic biochemistry, delay histological progression and improve transplant-free survival. Approximately 30–40% of patients do not respond or are intolerant to UDCA. Obeticholic acid,...

Descripción completa

Detalles Bibliográficos
Autor principal:	Floreani, Annarosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751712/ https://www.ncbi.nlm.nih.gov/pubmed/33364858 http://dx.doi.org/10.2147/JEP.S267375

Ejemplares similares

Update on the Pharmacological Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report
por: Del Ross, Teresa, et al.
Publicado: (2016)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study
por: Turco, Matteo, et al.
Publicado: (2018)

Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis
por: Arsenijevic, Aleksandar, et al.
Publicado: (2017)

New treatments/targets for primary biliary cholangitis
por: Corpechot, Christophe, et al.
Publicado: (2019)

Primary biliary cholangitis: Epidemiology, prognosis, and treatment
por: Trivella, Juan, et al.
Publicado: (2023)

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
por: Harms, Maren H., et al.
Publicado: (2020)

Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis
por: Overi, Diletta, et al.
Publicado: (2022)

Update on Emerging Treatment Options for Primary Biliary Cholangitis
por: Aguilar, Maria T, et al.
Publicado: (2020)

Recent advances in the diagnosis and treatment of primary biliary cholangitis
por: Huang, Ying-Qiu
Publicado: (2016)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Current understanding of primary biliary cholangitis
por: Tanaka, Atsushi
Publicado: (2021)

The Role of Epigenetics in Primary Biliary Cholangitis
por: Gerussi, Alessio, et al.
Publicado: (2022)

Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
por: Barba Bernal, Romelia, et al.
Publicado: (2023)

Biomarkers for primary biliary cholangitis: current perspectives
por: Kouroumalis, Elias, et al.
Publicado: (2018)

Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis
por: Cazzagon, Nora, et al.
Publicado: (2021)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis
por: Joshita, Satoru, et al.
Publicado: (2017)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis
por: Reshetnyak, Vasiliy I., et al.
Publicado: (2022)

Role of autoantibodies in the clinical management of primary biliary cholangitis
por: Rigopoulou, Eirini I, et al.
Publicado: (2023)

Animal models of primary biliary cholangitis: status and challenges
por: Wang, Xu, et al.
Publicado: (2023)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
por: Colapietro, Francesca, et al.
Publicado: (2023)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Primary biliary cholangitis: pathogenic mechanisms
por: Prieto, Jesús, et al.
Publicado: (2021)

Predicting Risk in Primary Biliary Cholangitis
por: Cho, Eun Ju
Publicado: (2023)

Toward solving the etiological mystery of primary biliary cholangitis
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Adam, Leonie, et al.
Publicado: (2018)

Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
por: Sclair, Seth N, et al.
Publicado: (2015)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review
por: Smith, Helen T., et al.
Publicado: (2023)

Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development
por: Arsenijevic, Aleksandar, et al.
Publicado: (2020)

Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
por: Trivedi, Hirsh D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9k8hjtpagtsi83f0iqhs6a8h6